Would you offer adjuvant chemotherapy to a post menopausal woman with T1-T3 primary tumor with 4 positive axillary LNs and OncotypeDX score less than 15?

Topics: Breast Cancer • Medical Oncology • HR+ • Breast Cancer, Non-metastatic

Answer from: Medical Oncologist at Academic Institution

The recurrence score and other genomic assays have been clinically useful in predicting chemotherapy benefit in HR+, HER2-, lymph-node–negative breast cancer and more recently in women with 1-3 positive lymph-nodes (Kalinsky et al., PMID 34914339). At this time, there is no role for genomic as...

Comments

Medical Oncologist at Florida Cancer Specialists and Research Institute
Dear Dr. @Yara Abdou, Is the line between 3 pos...

Medical Oncologist at University of North Carolina at Chapel Hill
At N2 disease, I would worry about using genomic...

Answer from: Medical Oncologist at Community Practice

In the global monarchE randomized phase III trial, patients with HR+, HER2−, node-positive, high-risk early breast cancer benefited from the addition of abemaciclib to standard adjuvant endocrine therapy with a statistically significant improvement in invasive disease free survival. High risk ...

Related Questions